187 related articles for article (PubMed ID: 36791582)
21. Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson's disease.
Zhao S; Chi H; Yang Q; Chen S; Wu C; Lai G; Xu K; Su K; Luo H; Peng G; Xia Z; Cheng C; Lu P
Front Immunol; 2023; 14():1090040. PubMed ID: 36825022
[TBL] [Abstract][Full Text] [Related]
22. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Analysis of the Tumor Immune Microenvironment Landscape in Glioblastoma Reveals Tumor Heterogeneity and Implications for Prognosis and Immunotherapy.
Zhao R; Pan Z; Li B; Zhao S; Zhang S; Qi Y; Qiu J; Gao Z; Fan Y; Guo Q; Qiu W; Wang S; Wang Q; Zhang P; Guo X; Deng L; Xue H; Li G
Front Immunol; 2022; 13():820673. PubMed ID: 35309323
[TBL] [Abstract][Full Text] [Related]
24. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
25. Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma.
Yu W; Ma Y; Hou W; Wang F; Cheng W; Qiu F; Wu P; Zhang G
Front Immunol; 2021; 12():706936. PubMed ID: 34899682
[TBL] [Abstract][Full Text] [Related]
26. Identification of INSRR as an immune-related gene in the tumor microenvironment of glioblastoma by integrated bioinformatics analysis.
Zhang H; Bao M; Liao D; Zhang Z; Tian Z; Yang E; Luo P; Jiang X
Med Oncol; 2023 Apr; 40(6):161. PubMed ID: 37099121
[TBL] [Abstract][Full Text] [Related]
27. Characterization of ferroptosis signature to evaluate the predict prognosis and immunotherapy in glioblastoma.
Zhu X; Zhou Y; Ou Y; Cheng Z; Han D; Chu Z; Pan S
Aging (Albany NY); 2021 Jul; 13(13):17655-17672. PubMed ID: 34244461
[TBL] [Abstract][Full Text] [Related]
28. Diverse Macrophages Constituted the Glioma Microenvironment and Influenced by PTEN Status.
Zhou F; Shi Q; Fan X; Yu R; Wu Z; Wang B; Tian W; Yu T; Pan M; You Y; Wang Y
Front Immunol; 2022; 13():841404. PubMed ID: 35265085
[TBL] [Abstract][Full Text] [Related]
29. The Heterogeneity of Tumour-Associated Macrophages Contributes to the Recurrence and Outcomes of Glioblastoma Patients.
Xuan Z; Fang L; Zhang G; Zhang X; Jiang J; Wang K; Huang P
J Mol Neurosci; 2023 Jan; 73(1):1-14. PubMed ID: 36542317
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the Immune Cell Infiltration Landscape and a New Prognostic Score in Glioblastoma.
Wang J; Chi S
J Healthc Eng; 2022; 2022():4326728. PubMed ID: 35310188
[TBL] [Abstract][Full Text] [Related]
31. Expression Profile Analysis Identifies a Novel Seven Immune-Related Gene Signature to Improve Prognosis Prediction of Glioblastoma.
Hu L; Han Z; Cheng X; Wang S; Feng Y; Lin Z
Front Genet; 2021; 12():638458. PubMed ID: 33708242
[TBL] [Abstract][Full Text] [Related]
32. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a novel mitophagy-related gene prognostic signature for glioblastoma multiforme.
Wang J; Qiu X; Huang J; Zhuo Z; Chen H; Zeng R; Wu H; Guo K; Yang Q; Ye H; Huang W; Luo Y
BMC Cancer; 2022 Jun; 22(1):644. PubMed ID: 35692054
[TBL] [Abstract][Full Text] [Related]
34. Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma.
Yang K; Shi Y; Luo M; Mao M; Zhang X; Chen C; Liu Y; He Z; Liu Q; Wang W; Luo C; Yin W; Wang C; Niu Q; Zeng H; Bian XW; Ping YF
Oncoimmunology; 2022; 11(1):2030020. PubMed ID: 35096487
[TBL] [Abstract][Full Text] [Related]
35. Prognosis and Immune Landscapes in Glioblastoma Based on Gene-Signature Related to Reactive-Oxygen-Species.
Kaushal P; Zhu J; Wan Z; Chen H; Ye J; Luo C
Neuromolecular Med; 2023 Mar; 25(1):102-119. PubMed ID: 35779207
[TBL] [Abstract][Full Text] [Related]
36. Correlation of genetic alterations by whole-exome sequencing with clinical outcomes of glioblastoma patients from the Lebanese population.
Saadeh FS; Morsi RZ; El-Kurdi A; Nemer G; Mahfouz R; Charafeddine M; Khoury J; Najjar MW; Khoueiry P; Assi HI
PLoS One; 2020; 15(11):e0242793. PubMed ID: 33237934
[TBL] [Abstract][Full Text] [Related]
37. The Non-N
Xu J; Gao Z; Liu K; Fan Y; Zhang Z; Xue H; Guo X; Zhang P; Deng L; Wang S; Wang H; Wang Q; Zhao R; Li G
Front Immunol; 2021; 12():809808. PubMed ID: 35154083
[TBL] [Abstract][Full Text] [Related]
38. Translational Nanomedicine Boosts Anti-PD1 Therapy to Eradicate Orthotopic PTEN-Negative Glioblastoma.
Kinoh H; Quader S; Shibasaki H; Liu X; Maity A; Yamasoba T; Cabral H; Kataoka K
ACS Nano; 2020 Aug; 14(8):10127-10140. PubMed ID: 32806051
[TBL] [Abstract][Full Text] [Related]
39. T cell-mediated tumor killing based signature to predict the prognosis and immunotherapy for glioblastoma.
Liu H; Shi K; Wei Z; Zhang Y; Li J
Heliyon; 2024 May; 10(10):e31207. PubMed ID: 38813229
[TBL] [Abstract][Full Text] [Related]
40. BACH1 as a potential target for immunotherapy in glioblastomas.
Yuan F; Cong Z; Cai X; Zhu J; Yuan L; Wang Y; Tang C; Ma C
Int Immunopharmacol; 2022 Feb; 103():108451. PubMed ID: 34923423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
